CA3226744A1 - Treatment of lupus - Google Patents
Treatment of lupus Download PDFInfo
- Publication number
- CA3226744A1 CA3226744A1 CA3226744A CA3226744A CA3226744A1 CA 3226744 A1 CA3226744 A1 CA 3226744A1 CA 3226744 A CA3226744 A CA 3226744A CA 3226744 A CA3226744 A CA 3226744A CA 3226744 A1 CA3226744 A1 CA 3226744A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- subject
- anifrolumab
- sle
- ifnar1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225974P | 2021-07-27 | 2021-07-27 | |
| US63/225,974 | 2021-07-27 | ||
| US202163254663P | 2021-10-12 | 2021-10-12 | |
| US63/254,663 | 2021-10-12 | ||
| PCT/EP2022/070860 WO2023006700A1 (en) | 2021-07-27 | 2022-07-26 | Treatment of lupus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226744A1 true CA3226744A1 (en) | 2023-02-02 |
Family
ID=83059135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226744A Pending CA3226744A1 (en) | 2021-07-27 | 2022-07-26 | Treatment of lupus |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250326850A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4377349A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527001A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240038773A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022317215A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226744A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310241A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340245A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006700A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD1120170S1 (en) * | 2024-03-28 | 2026-03-24 | Karsten Manufacturing Corporation | Golf club head |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| PT2418220T (pt) | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| ES2643237T3 (es) | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| SMT201700063T1 (it) | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
| CN104603152A (zh) * | 2012-06-13 | 2015-05-06 | 米迪缪尼有限公司 | 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
-
2022
- 2022-07-26 AU AU2022317215A patent/AU2022317215A1/en active Pending
- 2022-07-26 TW TW111127870A patent/TW202340245A/zh unknown
- 2022-07-26 IL IL310241A patent/IL310241A/en unknown
- 2022-07-26 CA CA3226744A patent/CA3226744A1/en active Pending
- 2022-07-26 US US18/291,671 patent/US20250326850A1/en active Pending
- 2022-07-26 KR KR1020247006291A patent/KR20240038773A/ko active Pending
- 2022-07-26 JP JP2024504491A patent/JP2024527001A/ja active Pending
- 2022-07-26 EP EP22758427.3A patent/EP4377349A1/en active Pending
- 2022-07-26 WO PCT/EP2022/070860 patent/WO2023006700A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024527001A (ja) | 2024-07-19 |
| TW202340245A (zh) | 2023-10-16 |
| AU2022317215A1 (en) | 2024-02-29 |
| WO2023006700A1 (en) | 2023-02-02 |
| IL310241A (en) | 2024-03-01 |
| KR20240038773A (ko) | 2024-03-25 |
| EP4377349A1 (en) | 2024-06-05 |
| US20250326850A1 (en) | 2025-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060429B2 (en) | Method of treating type 1 interferon (IFN)-mediated disease using a subcutaneous dosing regimen comprising anifrolumab | |
| AU2021356122B2 (en) | Treatment of flares in lupus | |
| US20250002589A1 (en) | Treatment of cutaneous lupus erythematous | |
| US20250002590A1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| US20250326850A1 (en) | Treatment of lupus | |
| US20250002591A1 (en) | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients | |
| CN117677638A (zh) | 狼疮的治疗 | |
| EA052183B1 (ru) | Лечение кожной красной волчанки | |
| JP2025533978A (ja) | ループスの治療 | |
| JP2024527001A5 (cg-RX-API-DMAC7.html) | ||
| HK40087032A (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| HK40087032B (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| IL324676A (en) | Lupus treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250626 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250812 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260619 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260619 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260722 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260722 |